Abstract:Invasive fungal infections have high morbidity and mortality rates and have become one of the most serious threats to human health. In the present study, a series of triazole antifungal derivatives with phenylthiophene backbone were obtained by structural modification of the lead compound using Iodiconazole as the lead compound. Among them, compound 19g is a triazole antifungal compound with 4-chloro-2-fluoro phenylthiophene backbone, which showed optimal antifungal activity against Candida albicans, Cryptococcus neoformans, and Aspergillus, with a MIC80 value of 0.0625 μg/mL. In addition, compounds 19e, 19f, 19g, 19h, 19i and 19k exhibited different levels of inhibitory activity against fluconazole-resistant strains with MIC80 values ranging from 0.0625 μg/mL to 32 μg/mL. Since compound 19g had optimal in vitro antifungal activity, we selected 19g for human liver microsomal stability and CYP enzyme inhibition assays as well as further evaluated the inhibitory activity of compound 19g on normal and cancerous cells in humans. Finally, we verified the inhibitory effect of compound 19g on the filamentation of Candida albicans and determined the mechanism of action by sterol composition analysis.

Design, Synthesis, and Structure-Activity Relationship Studies of Novel Triazole Agents with Strong Antifungal Activity Against Aspergillus Fumigatus

Molecular Docking, Design, Synthesis and Antifungal Activity Study of Novel Triazole Derivatives

Design, Synthesis of Novel Antifungal Triazole Derivatives with High Activities Against Aspergillus Fumigatus

Design, synthesis and in vitro biological studies of novel triazoles with potent and broad-spectrum antifungal activity

Design, synthesis and <i>in vitro</i> biological studies of novel triazoles with potent and broad-spectrum antifungal activity

Design, synthesis and molecular docking studies of novel triazole as antifungal agent.

Design, synthesis, and biological evaluation of novel 1, 2, 4-triazole derivatives as antifungal agent

Design, Synthesis, and in Vitro Evaluation of Novel Triazole Analogues Featuring Isoxazole Moieties As Antifungal Agents.

Synthesis, Molecular Docking, and Biological Evaluation of Novel Triazole Derivatives as Antifungal Agents

Molecular Docking, Design, Synthesis and Antifungal Activity Study of Novel Triazole Derivatives Containing the 1,2,3-Triazole Group

Design, Synthesis, and In Vitro and In Vivo Antifungal Activity of Novel Triazoles Containing Phenylethynyl Pyrazole Side Chains

Design, synthesis, and in vitro evaluation of novel antifungal triazoles containing substituted 1,2,3-triazole-methoxyl side chains

Design, Synthesis, Evaluation and Optimization of Novel Azole Analogues As Potent Antifungal Agents

Design, Synthesis and Antifungal Evaluation of 1-(2-(2,4-Difluorophenyl)-2-hydroxy-3-(1h-1,2,4-triazol-1-yl)propyl)-1h-1,2,4-triazol-5(4h)-one

Synthesis and Evaluation of Novel Azoles As Potent Antifungal Agents

Design, synthesis and antifungal activity of novel triazole derivatives containing substituted 1,2,3-triazole-piperdine side chains.

Novel conformationally restricted triazole derivatives with potent antifungal activity.

Design, synthesis and antifungal activities of novel 1,2,4-triazole derivatives.

Design, synthesis, and antifungal activity of novel conformationally restricted triazole derivatives.

Design, synthesis and bioactivity evaluation of triazole antifungal drugs with phenylthiophene structure

Design, synthesis, and antifungal activities of novel 1H-triazole derivatives based on the structure of the active site of fungal lanosterol 14 alpha-demethylase (CYP51).